RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2011 - 2025)

RedHill Biopharma (RDHL) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $25.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 40.47% year-over-year to $25.3 million in Q4 2025; TTM through Dec 2025 was $83.8 million, a 14.63% decrease from a year earlier, with the FY2025 full-year figure at $25.3 million, up 40.47% from the prior year.
• Liabilities and Shareholders Equity was $25.3 million for Q4 2025 at RedHill Biopharma, up from $18.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $220.1 million in Q1 2021 and troughed at $18.0 million in Q4 2024.
• A 5-year average of $109.5 million and a median of $157.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 53.42% in 2021 and plunged 85.49% in 2023, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $181.2 million in 2021, then dropped by 12.32% to $158.9 million in 2022, then sank by 85.49% to $23.0 million in 2023, then declined by 21.71% to $18.0 million in 2024, then jumped by 40.47% to $25.3 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $25.3 million (Q4 2025), $18.4 million (Q2 2025), and $18.0 million (Q4 2024), per Business Quant data.